[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.129.96. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 752
Citations 0
Clinical Trials Update
November 22/29, 2016

Low Prostate-Cancer Mortality No Matter the Treatment

JAMA. 2016;316(20):2078. doi:10.1001/jama.2016.17035

Deaths from localized prostate cancer 10 years after detection by prostate-specific antigen (PSA) testing were about 1% regardless of treatment, according to a trial published in The New England Journal of Medicine.

A total of 1643 men (median age of 62 years) were randomly assigned to active monitoring, surgery, or radiotherapy. The men’s median PSA level was 4.6 ng per milliliter, 77% had tumors with a Gleason score of 6 (on a scale from 6 to 10, with higher scores indicating a worse prognosis), and 76% had stage T1c, or nonpalpable, disease. Men in the active-monitoring group were able to switch to radical treatment based on changes in their PSA levels. A quarter of this group received radical treatment within 3 years and over half by 10 years.

First Page Preview View Large
First page PDF preview
First page PDF preview
×